Table 2 Clinical parameters involved in glucose and selenium metabolism at baseline and 4-year follow-up.

From: Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population

Characteristics

Baseline

4-year follow-up

P

n

76

76

 

BMI (kg/m2)

22.8 ± 3.0

22.8 ± 2.9

0.945

Fasting plasma glucose (mg/dl)

92.5 ± 8.4

97.1 ± 9.6

 <0.001**

Plasma glucose 30 min (mg/dl)

144.2 ± 25.2

149.3 ± 31.1

0.061

Plasma glucose 60 min (mg/dl)

131.3 ± 40.5

144.3 ± 45.2

0.004**

Plasma glucose 120 min (mg/dl)

109.0 ± 24.7

116.0 ± 26.0

0.022*

Fasting IRI (µU/ml)

5.7 ± 2.9

4.9 ± 2.6

0.025*

IRI 30 min (µU/ml)

47.9 ± 27.4

40.7 ± 33.5

0.141

IRI 60 min (µU/ml)

47.1 ± 24.8

46.6 ± 31.6

0.884

IRI120 min (µU/ml)

34.3 ± 20.4

33.0 ± 20.7

0.652

HbA1c (%)

5.2 ± 0.3

5.2 ± 0.3

0.763

HOMA-IR

1.31 ± 0.71

1.18 ± 0.67

0.152

Insulinogenic index

0.93 ± 0.69

0.69 ± 0.51

0.001**

SELENOP (μg/mL)

2.51 ± 0.52

3.81 ± 0.60

<0.001**

Selenium (μg/L) (n = 44)

157.9 ± 21.7

205.0 ± 22.1

0.075

GPX3 (U/L) (n = 44)

190.4 ± 68.5

238.3 ± 55.2

<0.001**

  1. Data are means ± SD.
  2. *p < 0.05, **p < 0.01.
  3. BMI, body mass index; IRI, immunoreactive insulin; HbA1c, glycosylated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; SELENOP, selenoprotein P; GPX3, glutathione peroxidase 3.
Back to article page